Library · Brain & nerves · Treatment of Cushing's disease and acromegaly
Pasireotide
SOM230, Signifor, Signifor LAR
A cyclohexapeptide somatostatin analogue from the 2000s with broader receptor binding than octreotide, especially at sst5. Approved by the FDA and EMA for Cushing's disease unsuited to surgery, and for acromegaly with inadequate surgical response.
Research score 90/100. Reference only, not a dose.
- Hormone Regulation
- Neuroprotective
- Anti-inflammatory
- Blood Sugar Control
- Appetite Suppression
- US status
- Prescription Only
- Approval
- FDA + EMA Approved
- Evidence
- FDA approved (Signifor) for Cushing's disease and Acromegaly. Shows superior efficacy to first-generation SSAs in certain receptor profiles.
- Research score
- 90 / 100
- Indication
- Cushing's Disease
- Origin
- Switzerland
- Source category
- Brain & Nervous System
- Status group
- Approved / prescription
Mechanism
Binds multiple somatostatin receptor subtypes, especially sst5, suppressing cAMP via G-protein signaling to curb ACTH secretion in Cushing's disease and GH/IGF-1 in acromegaly, aided by calcium-channel and phosphorylation effects.
Safety file
High blood sugar is the most common significant risk and needs monitoring; GI upset, gallstones, and QT prolongation are also concerns.
- Hyperglycemia
- Diabetes mellitus
- Diarrhea
- Nausea
- Abdominal pain
- Gallbladder problems
- QT interval prolongation